MARKSANS2023-10-012023-12-31 MARKSANS2023-10-012023-12-31 MARKSANS2023-10-012023-12-31in-bse-fin:OneOperatingExpenses01Member MARKSANS2023-10-012023-12-31in-bse-fin:FourOperatingExpenses01Member MARKSANS2023-12-31 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 524404 MARKSANS NOTLISTED Marksans Pharma Limited Equity 2023-04-01 2024-03-31 2024-02-13 2024-01-17 INR Millions Third quarter 13:00:00 14:15:00 2024-02-13 2024-02-13 Not applicable Single segment Manufacturing & Marketing of Pharmaceutical Formulations 2023-10-01 2023-12-31 Unaudited Standalone 2413640000.00 13250000.00 2426890000.00 1171630000.00 221150000.00 -14630000.00 204690000.00 2670000.00 84340000.00 411050000.00 2080900000.00 345990000.00 0.00 345990000.00 92230000.00 890000.00 93120000.00 0.00 252870000.00 0.00 0.00 0.00 0.00 252870000.00 -1620000.00 251250000.00 251250000.00 0.00 453160000.00 1 0.56 0.56 0.00 0.00 0.56 0.56 1. The unaudited standalone financial results for the quarter and nine months ended 31 December 2023 were reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on 13 February 2024. The Statutory Auditors of the Company have carried out limited review on the above results in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements} Regulations, 2015 ('the Regulation'}, as amended and expressed an unmodified conclusion. 2. The unaudited standalone financial results of the Company have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognised accounting principles generally accepted in India and in terms of the Regulation. 3 The Company operates in one reportable business segment namely 'Pharmaceuticals' as per Ind AS 108 on 'Operating Segments'. 4 On 19 April 2023, the Company has completed the acquisition of manufacturing facility relating to the manufacture and supply of pharmaceutical formulations in Goa from Tevapharm India Private Limited as a going concern on a slump sale basis. Manufacturing site is spread across 47,597 square meters. This manufacturing facility has approvals to manufacture products from EU, Health Canada and Japanese Health Authority. The transaction is in cash consideration of Rs. 779.47 million for the manufacturing facility (excluding transaction costs of Rs. 45. 78 million). The acquisition cost has been allocated to the individual identifiable assets based on their relative fair values at the date of purchase viz., 19 April 2023. 5 The above unaudited standalone financials results of the Company are available on the Company's Website (www.marksanspharma.com) and stock exchanges websites, BSE (www.bseindia.com) and NSE (www.nseindia.com), where the shares of the Company are listed. Single segment 2023-04-01 2023-12-31 Unaudited Standalone 6280780000.00 498790000.00 6779570000.00 3027870000.00 586460000.00 -51160000.00 556290000.00 7600000.00 216560000.00 1101010000.00 5444630000.00 1334940000.00 0.00 1334940000.00 284100000.00 43190000.00 327290000.00 0.00 1007650000.00 0.00 0.00 0.00 0.00 1007650000.00 -4880000.00 1002770000.00 1002770000.00 0.00 453160000.00 1 2.22 2.22 0.00 0.00 2.22 2.22 Other expenses 411050000.00 Other expenses 1101010000.00 -2170000.00 -6520000.00 -550000.00 -1640000.00 0.00 0.00